Skip to main content
Top

Cancer Chemotherapy and Pharmacology

Issue 6/2020

Content (17 Articles)

Biomarkers Editorial

NUC-1031 in biliary tract cancer: from bench to bedside and back?

Lenka N. C. Boyd, Godefridus J. Peters, Geert Kazemier, Elisa Giovannetti

Metastasis Original Article

Detection of trifluridine in tumors of patients with metastatic colorectal cancer treated with trifluridine/tipiracil

Yoshiaki Fujimoto, Ryota Nakanishi, Mamoru Nukatsuka, Kazuaki Matsuoka, Koji Ando, Takeshi Wakasa, Hiroyuki Kitao, Eiji Oki, Yoshihiko Maehara, Masaki Mori

Open Access Paracetamol Original Article

In vivo assessment of the drug interaction between sorafenib and paracetamol in rats

Agnieszka Karbownik, Katarzyna Sobańska, Tomasz Grabowski, Joanna Stanisławiak-Rudowicz, Anna Wolc, Edmund Grześkowiak, Edyta Szałek

Cholangiocarcinoma Original Article

Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer

Mansi Arora, James M. Bogenberger, Amro Abdelrahman, Jennifer L. Leiting, Xianfeng Chen, Jan B. Egan, Aradhana Kasimsetty, Elzbieta Lenkiewicz, Smriti Malasi, Pedro Luiz Serrano Uson, Bolni Marius Nagalo, Yumei Zhou, Marcela A. Salomao, Heidi E. Kosiorek, Esteban Braggio, Michael T. Barrett, Mark J. Truty, Mitesh J. Borad

Gastric Cancer Original Article

MEK inhibition overcomes everolimus resistance in gastric cancer

Hongfang Liu, Yang Yao, Juan Zhang, Jing Li

Solid Tumor Original Article

A phase I dose-escalation study of the polyamine analog PG-11047 in patients with advanced solid tumors

Tracy Murray Stewart, Apurva A. Desai, Michael L. Fitzgerald, Laurence J. Marton, Robert A. Casero Jr.

Original Article

Anticancer effects of brusatol in nasopharyngeal carcinoma through suppression of the Akt/mTOR signaling pathway

Songbin Guo, Jinling Zhang, Cairong Wei, Zhiyong Lu, Rulong Cai, Danqi Pan, Hanbin Zhang, Baoxia Liang, Zhenfeng Zhang

Pharmacokinetics Original Article

Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment

Ken Ogasawara, William B. Smith, Christine Xu, Jian Yin, Maria Palmisano, Gopal Krishna

Pharmacokinetics Original Article

Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients

Natsumi Matsumoto, Yutaro Kubota, Hiroo Ishida, Masae Sekido, Ryotaro Ohkuma, Tomoyuki Ishiguro, Yuya Hirasawa, Hirotsugu Ariizumi, Takuya Tsunoda, Toshikazu Ikusue, Kouji Kobayashi, Atsushi Hisamatsu, Hirokazu Toshima, Ken Shimada, Ken-ichi Fujita

Open Access Breast Cancer Original Article

Exposure–response analysis of endoxifen serum concentrations in early-breast cancer

Anabel Beatriz Sanchez-Spitman, Dirk-Jan A. R. Moes, Jesse J. Swen, Vincent O. Dezentjé, Diether Lambrechts, Patrick Neven, Hans Gelderblom, Henk-Jan Guchelaar

Ivermectin Original Article

Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug

Mandy Juarez, Alejandro Schcolnik-Cabrera, Guadalupe Dominguez-Gomez, Alma Chavez-Blanco, Jose Diaz-Chavez, Alfonso Duenas-Gonzalez

osteosarcoma Original Article

In vitro drug sensitivity (IDS) of patient-derived primary osteosarcoma cells as an early predictor of the clinical outcomes of osteosarcoma patients

Jeerawan Klangjorhor, Areerak Phanphaisarn, Pimpisa Teeyakasem, Parunya Chaiyawat, Phichayut Phinyo, Jongkolnee Settakorn, Nipon Theera-Umpon, Dumnoensun Pruksakorn

Glioblastoma Short Communication

CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model

J. H. Azambuja, R. S. Schuh, L. R. Michels, N. E. Gelsleichter, L. R. Beckenkamp, G. S. Lenz, F. H. de Oliveira, M. R. Wink, M. A. Stefani, A. M. O. Battastini, H. F. Teixeira, E. Braganhol

Expression of Concern

Expression of Concern: shRNA-mediated silencing of ZFX attenuated the proliferation of breast cancer cells

Hongjian Yang, Yue Lu, Yabing Zheng, Xingfei Yu, Xianghou Xia, Xiangming He, Weiliang Feng, Lei Xing, Zhiqiang Ling

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine